SCHEMBL6927775

SCHEMBL6927775

O=C(Nc1ccccn1)c1ccc(OCc2ccccc2)nc1

nearest known ligand 0.73

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CXCR2 P25025 3/20 0.73
SGMS2 Q8NHU3 1/20 0.60
RAB9A P51151 6/20 0.58
NPC1 O15118 5/20 0.58
GCK P35557 2/20 0.56
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
CXCR1 P25024 1/20 0.53
F2 P00734 1/20 0.52
CHRNB2 P17787 1/20 0.50
CHRNB4 P30926 1/20 0.50
CHRNA3 P32297 1/20 0.50
CHRNA4 P43681 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.49
USP2 O75604 1/20 0.49
TP53 P04637 1/20 0.49
CYP1A2 P05177 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6930026 0.93 CXCR2 (0.64) CXCR2SGMS2RAB9ANPC1GCK
SCHEMBL6930364 0.91 CXCR2 (0.74) CXCR2SGMS2RAB9ANPC1MEN1
SCHEMBL6929931 0.91 CXCR2 (0.61) CXCR2SGMS2RAB9ANPC1GCK
SCHEMBL6930256 0.88 CXCR2 (0.58) CXCR2SGMS2RAB9ANPC1GCK
SCHEMBL6931210 0.87 CXCR2 (0.69) CXCR2SGMS2RAB9AGCKMEN1
SCHEMBL6927997 0.84 CXCR2 (1.00) CXCR2GCKMEN1KMT2ACXCR1
SCHEMBL12398724 0.84 CXCR2 (0.76) CXCR2RAB9ANPC1GCKMEN1
SCHEMBL6927893 0.84 CXCR2 (0.68) CXCR2SGMS2RAB9ANPC1MEN1
SCHEMBL6927759 0.83 CXCR2 (0.60) CXCR2RAB9ANPC1GCKMEN1
SCHEMBL12398777 0.83 CXCR2 (0.64) CXCR2RAB9ANPC1KMT2ACHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110183980-A1 O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-07-28 US disclosed
US-20110183980-A1 O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-07-28 US disclosed
WO-2011035324-A1 O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS VANDERBILT UNIVERSITY (US) 2011-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183980-A1 O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS GRM5, GRIK5, GRM1 CXCR2 2454/4885SGMS2 2235/4885RAB9A 1383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.